HeartBeam Granted European Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

Author's Avatar
Jan 05, 2023

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced today that its patent that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo™ credit card-sized device was issued by the European Patent Office. This patent offers protection for HeartBeam’s flagship technology in multiple countries in Europe and has been validated in France, Germany, Netherlands and the United Kingdom. The innovation opens the pathway for a patient to record a set of signals using HeartBeam AIMIGo outside of a medical setting with a diagnostic synthesized 12-lead ECG immediately transmitted to a physician for review and diagnosis.